MARIETTA, Ga., May 8, 2015 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ:MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that Novation has recognized MiMedx as a recipient of Novation’s Innovative Technology award for 2015. MiMedx also announced that it has entered into a national agreement with Novation.
Novation is the country’s leading health care services company for the more than 100,000 members and affiliates of VHA Inc., UHC, Children’s Hospital Association, and Provista LLC.
Parker H. Petit, MiMedx Chairman and CEO, said, “We are extremely honored to announce that MiMedx has received an Innovative Technology award from Novation. We are also very pleased to provide our EpiFix® and AmnioFix® allografts to the members and affiliate organizations served by Novation.” 
The national contract with Novation will be effective on June 1, 2015, and the more than 100,000 members and affiliates they represent will be offered MiMedx allografts through Novation. “We have made substantial investments and dedicated significant resources in the development of our proprietary technology, the production of our Compendium of clinical and scientific study results, and the attainment of rapid coverage acceptance among health plans. MiMedx was awarded the Innovative Technology award following a review by more than 200 attendees from hospitals around the United States who serve on a Novation council or task force and participated in the Expo,” stated Petit.
“This new designation will identify MiMedx as an awarded Innovative Technology product within Novation’s online contract catalog. This heightened visibility will encourage further consideration by members accessing this agreement,” added Petit.
Bill Taylor, MiMedx President and COO, commented, “We are continually increasing the base of patients who have access to and can benefit from our clinically effective and cost effective allografts. This major contract will now offer hundreds of thousands of patients our proprietary technology through the Novation portfolio.”